- Cempra to Host Conference Call and Webcast at 4:30 p.m. EDT, Today, May 13, 2013 - CHAPEL HILL, N.C. , May 13, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP) , a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical needs in the treatment of bacterial infections, today announced the signing of an exclusive license and development agreement for solithromycin with Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation in Japan .
Sign-up for Cempra, Inc. Signs Exclusive License and Development Agreement for Solithromycin with Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation in Japan investment picks